Neutrophil-Lymphocyte Ratio Predicts Survival in Terminal Cancer Patients.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 26886409.
- Also identified by DOI 10.1089/jpm.2015.0277.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Neutrophil-lymphocyte count ratio (NLR) is a prognostic factor in cancer, although its prognostic significance in terminally ill cancer patients is not clear. We investigated the association of NLR with survival in patients with terminal cancer. We retrospectively investigated 205 consecutive patients with terminal cancer admitted to a palliative care unit during 2014. The median value of NLR was 9.7. In univariable analysis, NLR of 10 or more was significantly associated with shorter survival and NLR further discriminated survival of each palliative prognostic index (PPI) group. In multivariable analysis, increased NLR (≥10) was associated with shorter survival (hazards ratio [HR] 1.54, p<0.005), along with poor performance status (HR 1.55, p < 0.011), high PPI score (HR 1.59, p<0.003), and hyperbilirubinemia (HR 1.84, p < 0.001). Our results suggest that elevated NLR was an independent prognostic factor for poor survival in patients with terminal cancer.
Medical subject headings
- Lymphocyte Count
- Neoplasms
- Neutrophils